Patent application EP16169487A (EP), filed 2016-05-13
Publication number: EP3243832A1
Title: ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER AND PD1 BINDING MOIETY
Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to PD1 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
IPC codes: A61K  39/   395            A I
C07K  14/   705            A I
C07K  16/    28            A I
C12N  15/    62            A I
Claims: number: 1
text: A TNF family ligand trimer-containing antigen binding molecule comprising
number: 2
text: The TNF family ligand trimer-containing antigen binding molecule of claim 1, further comprising
number: 3
text: The TNF family ligand trimer-containing antigen binding molecule of claims 1 or 2, comprising
number: 4
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 3, wherein the TNF ligand family member is selected from 4-1BBL and OX40L.
number: 5
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 4, wherein the TNF ligand family member is 4-1BBL.
number: 6
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 5, wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7 and SEQ ID NO:8, particularly the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:5.
number: 7
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 6, comprising
number: 8
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 7, wherein the moiety capable of specific binding to PD1 is a Fab molecule capable of specific binding to PD1.
number: 9
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 8, wherein the moiety capable of specific binding to PD1 comprises
number: 10
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 9, wherein the moiety capable of specific binding to PD1 comprises
number: 11
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 10, wherein the antigen binding molecule comprises
a first heavy chain and a first light chain, both comprising a Fab molecule capable of specific binding to PD1,
a first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker fused at its C-terminus by a second peptide linker to a second heavy or light chain,
and a second peptide comprising one ectodomain of said TNF ligand family member fused at its C-terminus by a third peptide linker to a second light or heavy chain, respectively.
number: 12
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 10, wherein the first peptide comprising two ectodomains of a TNF ligand family member or fragments thereof connected to each other by a first peptide linker is fused at its C-terminus by a second peptide linker to a CL domain that is part of a heavy chain,
and the second peptide comprising one ectodomain of said TNF ligand family member or a fragment thereof is fused at its C-terminus by a third peptide linker to a CH1 domain that is part of a light chain.
number: 13
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 10, comprising
number: 14
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 10, wherein the antigen binding molecule comprises
number: 15
text: The TNF family ligand trimer-containing antigen binding molecule of any one of claims 1 to 14 for use in the treatment of cancer.
Office action: search_report, dated 2017-11-15
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: WO2010010051A1
ref_type: patent
severity: background
ref_id: WO03042402A2
ref_type: patent
severity: background
ref_id: WO2004004771A1
ref_type: patent
severity: background
ref_id: WO2004056875A1
ref_type: patent
severity: background
ref_id: WO2004072286A1
ref_type: patent
severity: background
ref_id: WO2004087196A2
ref_type: patent
severity: background
ref_id: WO2006121168A1
ref_type: patent
severity: background
ref_id: WO2006133396A2
ref_type: patent
severity: background
ref_id: WO2007005874A2
ref_type: patent
severity: background
ref_id: WO2008083174A2
ref_type: patent
severity: background
ref_id: WO2008156712A1
ref_type: patent
severity: background
ref_id: WO2009024531A1
ref_type: patent
severity: background
ref_id: WO2009014708A2
ref_type: patent
severity: background
ref_id: WO2009101611A1
ref_type: patent
severity: background
ref_id: WO2009114335A2
ref_type: patent
severity: background
ref_id: WO2009154335A1
ref_type: patent
severity: background
ref_id: WO2010027828A2
ref_type: patent
severity: background
ref_id: WO2010027423A2
ref_type: patent
severity: background
ref_id: WO2010029434A1
ref_type: patent
severity: background
ref_id: WO2010029435A1
ref_type: patent
severity: background
ref_id: WO2010036959A2
ref_type: patent
severity: background
ref_id: WO2010063011A2
ref_type: patent
severity: background
ref_id: WO2010089411A2
ref_type: patent
severity: background
ref_id: WO2011066342A2
ref_type: patent
severity: background
ref_id: WO2011110604A1
ref_type: patent
severity: background
ref_id: WO2011110621A1
ref_type: patent
severity: background
ref_id: WO2012145493A1
ref_type: patent
severity: background
ref_id: WO2013014668A1
ref_type: patent
severity: background
ref_id: WO2014179664A2
ref_type: patent
severity: background
ref_id: WO2015112900A1
ref_type: patent
severity: background
ref_id: WO0220565A2
ref_type: patent
severity: background
ref_id: WO9316185A2
ref_type: patent
severity: background
ref_id: US5571894A
ref_type: patent
severity: background
ref_id: US5587458A
ref_type: patent
severity: background
ref_id: US5869046A
ref_type: patent
severity: background
ref_id: EP0404097A2
ref_type: patent
severity: background
ref_id: WO9301161A1
ref_type: patent
severity: background
ref_id: US6248516B1
ref_type: patent
severity: background
ref_id: US7166697B1
ref_type: patent
severity: background
ref_id: US7250297B1
ref_type: patent
severity: background
ref_id: US2007224633A1
ref_type: patent
severity: background
ref_id: EP1641818A1
ref_type: patent
severity: background
ref_id: US2004132028A1
ref_type: patent
severity: background
ref_id: US2008139791A1
ref_type: patent
severity: background
ref_id: WO2005056764A2
ref_type: patent
severity: background
ref_id: US6818418B1
ref_type: patent
severity: background
ref_id: WO2008098796A1
ref_type: patent
severity: background
ref_id: US5821333A
ref_type: patent
severity: background
ref_id: US5731168A
ref_type: patent
severity: background
ref_id: US7695936B2
ref_type: patent
severity: background
ref_id: US2003157108A1
ref_type: patent
severity: background
ref_id: US2004093621A1
ref_type: patent
severity: background
ref_id: WO03011878A2
ref_type: patent
severity: background
ref_id: US6602684B1
ref_type: patent
severity: background
ref_id: US2005123546A1
ref_type: patent
severity: background
ref_id: WO9730087A1
ref_type: patent
severity: background
ref_id: WO9858964A1
ref_type: patent
severity: background
ref_id: WO9922764A1
ref_type: patent
severity: background
ref_id: US7521541B2
ref_type: patent
severity: background
ref_id: WO2012130831A1
ref_type: patent
severity: background
ref_id: US6737056B1
ref_type: patent
severity: background
ref_id: US7332581B2
ref_type: patent
severity: background
ref_id: US5500362A
ref_type: patent
severity: background
ref_id: US5821337A
ref_type: patent
severity: background
ref_id: WO2006029879A2
ref_type: patent
severity: background
ref_id: WO2005100402A1
ref_type: patent
severity: background
ref_id: WO2009089004A1
ref_type: patent
severity: background
ref_id: US5959177A
ref_type: patent
severity: background
ref_id: US6040498A
ref_type: patent
severity: background
ref_id: US6420548B1
ref_type: patent
severity: background
ref_id: US7125978B1
ref_type: patent
severity: background
ref_id: US6417429B1
ref_type: patent
severity: background
ref_id: US4186567A
ref_type: patent
severity: background
ref_id: US5969108A
ref_type: patent
severity: background
ref_id: US5565332A
ref_type: patent
severity: background
ref_id: US7527791B2
ref_type: patent
severity: background
ref_id: US6982321B2
ref_type: patent
severity: background
ref_id: US7087409B2
ref_type: patent
severity: background
ref_id: WO2012020006A2
ref_type: patent
severity: background
ref_id: US2004132066A1
ref_type: patent
severity: background
ref_id: US2005260186A1
ref_type: patent
severity: background
ref_id: US2006104968A1
ref_type: patent
severity: background
ref_id: US6267958B1
ref_type: patent
severity: background
ref_id: US6171586B1
ref_type: patent
severity: background
ref_id: WO2006044908A2
ref_type: patent
severity: background
ref_id: WO2015150447A1
ref_type: patent
severity: background
ref_id: - BANNER ET AL., CELL, vol. 73, 1993, pages 431 - 445
ref_type: npl
severity: background
ref_id: - OKAZAKI ET AL., CURR. OPIN. IMMUNOL, vol. 14, 2002, pages 391779 - 82
ref_type: npl
severity: background
ref_id: - BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8
ref_type: npl
severity: background
ref_id: - SHERIDAN, NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 729 - 730
ref_type: npl
severity: background
ref_id: - KOYAMA ET AL., NATURE COMMUNICATIONS, 2016
ref_type: npl
severity: background
ref_id: - HUDSON ET AL., NAT MED, vol. 9, 2003, pages 129 - 134
ref_type: npl
severity: background
ref_id: - PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
ref_type: npl
severity: background
ref_id: - HOLLINGER ET AL., PROC NATL ACAD SCI USA, vol. 90, 1993, pages 6444 - 6448
ref_type: npl
severity: background
ref_id: - HOUSTON, J.S., METHODS IN ENZYMOL., vol. 203, 1991, pages 46 - 96
ref_type: npl
severity: background
ref_id: - GEBAUER; SKERRA: "Engineered protein scaffolds as next-generation antibody therapeutics", CURR OPIN CHEM BIOL, vol. 13, 2009, pages 245 - 255
ref_type: npl
severity: background
ref_id: - STUMPP ET AL.: "Darpins: A new generation of protein therapeutics", DRUG DISCOVERY TODAY, vol. 13, 2008, pages 695 - 701, XP023440383, DOI: doi:10.1016/j.drudis.2008.04.013
ref_type: npl
severity: background
ref_id: - JOURNAL OF IMMUNOLOGICAL METHODS, vol. 248, no. 1-2, 2001, pages 31 - 45
ref_type: npl
severity: background
ref_id: - BIOCHIM BIOPHYS ACTA, vol. 1482, 2000, pages 337 - 350
ref_type: npl
severity: background
ref_id: - PROTEIN ENG. DES. SEL., vol. 17, 2004, pages 455 - 462
ref_type: npl
severity: background
ref_id: - NATURE BIOTECHNOLOGY, vol. 23, no. 12, 2005, pages 1556 - 1561
ref_type: npl
severity: background
ref_id: - EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 16, no. 6, June 2007 (2007-06-01), pages 909 - 917
ref_type: npl
severity: background
ref_id: - J. BIOL. CHEM, vol. 274, 1999, pages 24066 - 24073
ref_type: npl
severity: background
ref_id: - J. MOL. BIOL., vol. 332, 2003, pages 489 - 503
ref_type: npl
severity: background
ref_id: - PNAS, vol. 100, no. 4, 2003, pages 1700 - 1705
ref_type: npl
severity: background
ref_id: - J. MOL. BIOL., vol. 369, 2007, pages 1015 - 1028
ref_type: npl
severity: background
ref_id: - PROTEIN ENG. DES. SEL., vol. 18, 2005, pages 435 - 444
ref_type: npl
severity: background
ref_id: - EXPERT OPIN. BIOL. THER., vol. 5, 2005, pages 783 - 797
ref_type: npl
severity: background
ref_id: - LILJEBLAD ET AL., GLYCO J, vol. 17, 2000, pages 323 - 329
ref_type: npl
severity: background
ref_id: - HEELEY, ENDOCR RES, vol. 28, 2002, pages 217 - 229
ref_type: npl
severity: background
ref_id: - ISHIDA ET AL., EMBO J., vol. 11, 1992, pages 3887 - 3895
ref_type: npl
severity: background
ref_id: - AGATA ET AL., INT. IMMUNOLOGY, vol. 8, 1996, pages 765 - 772
ref_type: npl
severity: background
ref_id: - CHINAI ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 36, 2015, pages 587 - 595
ref_type: npl
severity: background
ref_id: - KINDT ET AL.: "Kuby Immunology,6th ed.,", 2007, W.H. FREEMAN AND CO., pages: 91
ref_type: npl
severity: background
ref_id: - CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
ref_type: npl
severity: background
ref_id: - KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th Ed.", 1991, NATIONAL INSTITUTES OF HEALTH
ref_type: npl
severity: background
ref_id: - KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1983, U.S. DEPT. OF HEALTH AND HUMAN SERVICES
ref_type: npl
severity: background
ref_id: - CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
ref_type: npl
severity: background
ref_id: - KABAT ET AL.: "Sequence of Proteins of Immunological Interest", 1983, U.S. DEPT. OF HEALTH AND HUMAN SERVICES
ref_type: npl
severity: background
ref_id: - ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633
ref_type: npl
severity: background
ref_id: - RIDGWAY ET AL., PROT ENG, vol. 9, 1996, pages 617 - 621
ref_type: npl
severity: background
ref_id: - CARTER, J IMMUNOL METH, vol. 248, 2001, pages 7 - 15
ref_type: npl
severity: background
ref_id: - CARTER, J IMMUNOL METHODS, vol. 248, 2001, pages 7 - 15
ref_type: npl
severity: background
ref_id: - BOWIE, J. U. ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 10
ref_type: npl
severity: background
ref_id: - CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
ref_type: npl
severity: background
ref_id: - WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32
ref_type: npl
severity: background
ref_id: - KAM, N.W. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605
ref_type: npl
severity: background
ref_id: - HELLSTROM ET AL., PROC NATL ACAD SCI USA, vol. 83, 1986, pages 7059 - 7063
ref_type: npl
severity: background
ref_id: - HELLSTROM ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 1499 - 1502
ref_type: npl
severity: background
ref_id: - BRUGGEMANN ET AL., J EXP MED, vol. 166, 1987, pages 1351 - 1361
ref_type: npl
severity: background
ref_id: - CLYNES ET AL., PROC NATL ACAD SCI USA, vol. 95, 1998, pages 652 - 656
ref_type: npl
severity: background
ref_id: - GAZZANO-SANTORO ET AL., J IMMUNOL METHODS, vol. 202, 1996, pages 163
ref_type: npl
severity: background
ref_id: - CRAGG ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052
ref_type: npl
severity: background
ref_id: - CRAGG; GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743
ref_type: npl
severity: background
ref_id: - MANIATIS ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", 1989, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - AUSUBEL ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1989, GREENE PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
ref_type: npl
severity: background
ref_id: - GERNGROSS, NAT BIOTECH, vol. 22, 2004, pages 1409 - 1414
ref_type: npl
severity: background
ref_id: - LI ET AL., NAT BIOTECH, vol. 24, 2006, pages 210 - 215
ref_type: npl
severity: background
ref_id: - GRAHAM ET AL., J GEN VIROL, vol. 36, 1977, pages 59
ref_type: npl
severity: background
ref_id: - MATHER, BIOL REPROD, vol. 23, 1980, pages 243 - 251
ref_type: npl
severity: background
ref_id: - MATHER ET AL.,, ANNALS N.Y. ACAD SCI, vol. 383, 1982, pages 44 - 68
ref_type: npl
severity: background
ref_id: - URLAUB ET AL., PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4216
ref_type: npl
severity: background
ref_id: - YAZAKI; WU: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies, a laboratory manual", 1988, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - ALMAGRO; FRANSSON, FRONT BIOSCI, vol. 13, 2008, pages 1619 - 1633
ref_type: npl
severity: background
ref_id: - RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ref_type: npl
severity: background
ref_id: - QUEEN ET AL., PROC NATL ACAD SCI USA, vol. 86, 1989, pages 10029 - 10033
ref_type: npl
severity: background
ref_id: - JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
ref_type: npl
severity: background
ref_id: - MORRISON ET AL., PROC NATL ACAD SCI, vol. 81, 1984, pages 6851 - 6855
ref_type: npl
severity: background
ref_id: - MORRISON; OI, ADV IMMUNOL, vol. 44, 1988, pages 65 - 92
ref_type: npl
severity: background
ref_id: - VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
ref_type: npl
severity: background
ref_id: - PADLAN, MOLEC IMMUN, vol. 31, no. 3, 1994, pages 169 - 217
ref_type: npl
severity: background
ref_id: - KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34
ref_type: npl
severity: background
ref_id: - PADLAN, MOL IMMUNOL, vol. 28, 1991, pages 489 - 498
ref_type: npl
severity: background
ref_id: - DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60
ref_type: npl
severity: background
ref_id: - OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68
ref_type: npl
severity: background
ref_id: - KLIMKA ET AL., BR J CANCER, vol. 83, 2000, pages 252 - 260
ref_type: npl
severity: background
ref_id: - VAN DIJK; VAN DE WINKEL, CURR OPIN PHARMACOL, vol. 5, 2001, pages 368 - 74
ref_type: npl
severity: background
ref_id: - LONBERG, CURR OPIN IMMUNOL, vol. 20, 2008, pages 450 - 459
ref_type: npl
severity: background
ref_id: - "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
ref_type: npl
severity: background
ref_id: - LONBERG, NAT BIOTECH, vol. 23, 2005, pages 1117 - 1125
ref_type: npl
severity: background
ref_id: - HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37
ref_type: npl
severity: background
ref_id: - MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554
ref_type: npl
severity: background
ref_id: - CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
ref_type: npl
severity: background
ref_id: - MORRIS: "Methods in Molecular Biology", vol. 66, 1996, HUMANA PRESS, article "Epitope Mapping Protocols"
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY, article "ch. 14"
ref_type: npl
severity: background
ref_id: - "Remington's Pharmaceutical Sciences, 18th Ed.", 1990, MACK PRINTING COMPANY
ref_type: npl
severity: background
ref_id: - FINGL ET AL.: "The Pharmacological Basis of Therapeutics", 1975, article "Ch. 1,", pages: 1
ref_type: npl
severity: background
ref_id: - KABAT, E.A. ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.,", 1991, NATIONAL INSTITUTES OF HEALTH
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular cloning: A laboratory manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - KABAT, E.A. ET AL.: "Sequences of Proteins of Immunological Interest, Fifth ed.,", 1991, NIH PUBLICATION NO 91-3242
ref_type: npl
severity: background
ref_id: - BONIFACINO, J.S., DASSO, M., HARFORD, J.B.,: "Current Protocols in Cell Biology", 2000, JOHN WILEY & SONS, INC
ref_type: npl
severity: background
ref_id: - ASCIERTO, P. A.; E. SIMEONE; M. SZNOL; Y. X. FU; I. MELERO: "Clinical experiences with anti-CD137 and anti-PD therapeutic antibodies", SEMIN ONCOL, vol. 37, 2010, pages 508 - 516, XP008175440, DOI: doi:10.1053/j.seminoncol.2010.09.008
ref_type: npl
severity: background
ref_id: - AGGARWAL B.B.: "Signalling pathways of the TNF superfamily: a double-edged sword", NAT. REV. IMMUNOL, vol. 3, no. 9, 2003, pages 745 - 56
ref_type: npl
severity: background
ref_id: - BANNER D. ET AL.: "Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation", CELL, vol. 73, 1993, pages 431 - 445
ref_type: npl
severity: background
ref_id: - BODMER J.; SCHNEIDER P.; TSCHOPP, J.: "The molecular architecture of the TNF superfamily", TRENDS IN BIOCHEMICAL SCIENCES, vol. 27, no. 1, 2002, pages 19 - 26, XP004332356, DOI: doi:10.1016/S0968-0004(01)01995-8
ref_type: npl
severity: background
ref_id: - BROLL, K.; RICHTER, G.; PAULY, S.; HOFSTAEDTER, F.; SCHWARZ, H.: "CD137 expression in tumor vessel walls. High correlation with malignant tumors", AM J CLIN PATHOL, vol. 115, 2001, pages 543 - 549, XP009028982, DOI: doi:10.1309/E343-KMYX-W3Y2-10KY
ref_type: npl
severity: background
ref_id: - BUECHELE, C.; BAESSLER, T.; SCHMIEDEL, B.J.; SCHUMACHER, C.E.; GROSSE-HOVEST, L.; RITTIG, K.; SALIH, H.R.: "4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.", EUR J IMMUNOL, vol. 42, 2012, pages 737 - 748
ref_type: npl
severity: background
ref_id: - CHEN S.; LEE L.; FISHER T.; JESSEN B.; ELLIOTT M.; EVERING W.; LOGRONIO K.; TU K.H.; TSAPARIKOS K.; LI X.: "Combination of 4-1BB Agonist and PD-1 I Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model.", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 2, 2015, pages 149 - 160, XP055293412, DOI: doi:10.1158/2326-6066.CIR-14-0118
ref_type: npl
severity: background
ref_id: - CHOI, B.K.; KIM, Y.H.; KWON, P.M.; LEE, S.C.; KANG, S.W.; KIM, M.S.; LEE, M.J.; KWON, B.S.: "4-1BB functions as a survival factor in dendritic cells", J IMMUNOL, vol. 182, 2009, pages 4107 - 4115
ref_type: npl
severity: background
ref_id: - CUADROS, C.; DOMINGUEZ, A.L.; LOLLINI, P.L.; CROFT, M.; MITTLER, R.S.; BORGSTROM, P.; LUSTGARTEN, J.: "Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice", INT J CANCER, vol. 116, 2005, pages 934 - 943
ref_type: npl
severity: background
ref_id: - CURRAN, M.A.; KIM, M.; MONTALVO, W.; AL-SHAMKHANI, A.; ALLISON, J.P.: "Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production", PLOS ONE, vol. 6, 2011, pages E19499
ref_type: npl
severity: background
ref_id: - DIEHL, L.; VAN MIERLO, G.J.; DEN BOER, A.T.; VAN DER VOORT, E.; FRANSEN, M.; VAN BOSTELEN, L.; KRIMPENFORT, P.; MELIEF, C.J.; MITT: "In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway", J IMMUNOL, vol. 168, 2002, pages 3755 - 3762, XP002238986
ref_type: npl
severity: background
ref_id: - DUBROT, J.; MILHEIRO, F.; ALFARO, C.; PALAZON, A.; MARTINEZ-FORERO, 1.; PEREZ-GRACIA, J.L.; MORALES-KASTRESANA, A.; ROMERO-TREVEJO: "Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.", CANCER IMMUNOL IMMUNOTHER, vol. 59, 2010, pages 1223 - 1233, XP019842192
ref_type: npl
severity: background
ref_id: - FUTAGAWA, T.; AKIBA, H.; KODAMA, T.; TAKEDA, K.; HOSODA, Y.; YAGITA, H.; OKUMURA, K.: "Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells", INT IMMUNOL, vol. 14, 2002, pages 275 - 286, XP002486148, DOI: doi:10.1093/intimm/14.3.275
ref_type: npl
severity: background
ref_id: - GUO, Z.; CHENG, D.; XIA, Z.; LUAN, M.; WU, L.; WANG, G.; ZHANG, S.: "Combined TIM-3 blockade and CD 137 activation affords the long-term protection in a murine model of ovarian cancer", J TRANSL MED, vol. 11, 2013, pages 215, XP021164386, DOI: doi:10.1186/1479-5876-11-215
ref_type: npl
severity: background
ref_id: - HEINISCH, LV.; DAIGLE, I.; KNOPFLI, B.; SIMON, H.U.: "CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils", EUR J IMMUNOL, vol. 30, 2000, pages 3441 - 3446
ref_type: npl
severity: background
ref_id: - HORNIG, N.; KERMER, V.; FREY, K.; DIEBOLDER, P.; KONTERMANN, RE.; MUELLER, D.: "Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy", J. IMMUNOTHER, vol. 35, 2012, pages 418 - 429, XP009163394, DOI: doi:10.1097/CJI.0b013e3182594387
ref_type: npl
severity: background
ref_id: - JU, S.A.; CHEON, S.H.; PARK, S.M.; TAM, N.Q.; KIM, Y.M.; AN, W.G.; KIM, B.S.: "Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice", INT J CANCER, vol. 122, 2008, pages 2784 - 2790
ref_type: npl
severity: background
ref_id: - KIENZLE, G.; VON KEMPIS, J.: "CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes", INT IMMUNOL, vol. 12, 2000, pages 73 - 82
ref_type: npl
severity: background
ref_id: - KIM, D.H.; CHANG, W.S.; LEE, Y.S.; LEE, K.A.; KIM, Y.K.; KWON, B.S.; KANG, C.Y.: "4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation", J IMMUNOL, vol. 180, 2008, pages 2062 - 2068
ref_type: npl
severity: background
ref_id: - KIM, Y.H.; CHOI, B.K.; OH, H.S.; KANG, W.J.; MITTLER, R.S.; KWON, B.S.: "Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy", MOL CANCER THER, vol. 8, 2009, pages 469 - 478, XP008159721, DOI: doi:10.1158/1535-7163.MCT-08-0993
ref_type: npl
severity: background
ref_id: - KWON, B.S.; WEISSMAN, S.M.: "cDNA sequences of two inducible T-cell genes", PROC NATL ACAD SCI U S A, vol. 86, 1989, pages 1963 - 1967
ref_type: npl
severity: background
ref_id: - LEE, H.; PARK, H.J.; SOHN, H.J.; KIM, J.M.; KIM, S.J.: "Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal", J SURG RES, vol. 169, 2011, pages E43 - 50
ref_type: npl
severity: background
ref_id: - LEVITSKY, V.; DE CAMPOS-LIMA, P.O.; FRISAN, T.; MASUCCI, M.G.: "The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time", J IMMUNOL, vol. 161, 1998, pages 594 - 601
ref_type: npl
severity: background
ref_id: - LI, P.; RAVETCH, J.V.: "Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies", SCIENCE, vol. 333, 2011, pages 1030 - 1034, XP002720021, DOI: doi:10.1126/science.1206954
ref_type: npl
severity: background
ref_id: - LIN, W.; VOSKENS, C.J.; ZHANG, X.; SCHINDLER, D.G.; WOOD, A.; BURCH, E.; WEI, Y.; CHEN, L.; TIAN, G.; TAMADA, K. ET AL.: "Fc-dependent expression of CD137 on human NK cells: insights into ''agonistic'' effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, 2008, pages 699 - 707, XP055037053, DOI: doi:10.1182/blood-2007-11-122465
ref_type: npl
severity: background
ref_id: - MELERO, I.; JOHNSTON, J.V.; SHUFFORD, W.W.; MITTLER, R.S.; CHEN, L.: "NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.", CELL IMMUNOL, vol. 190, 1998, pages 167 - 172
ref_type: npl
severity: background
ref_id: - MELERO, I.; SHUFORD, W.W.; NEWBY, S.A.; ARUFFO, A.; LEDBETTER, J.A.; HELLSTROM, K.E.; MITTLER, R.S.; CHEN, L.: "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.", NAT MED, vol. 3, 1997, pages 682 - 685, XP002104261, DOI: doi:10.1038/nm0697-682
ref_type: npl
severity: background
ref_id: - MERCHANT, A.M.; ZHU, Z.; YUAN, J.Q.; GODDARD, A.; ADAMS, C.W.; PRESTA, L.G.; CARTER, P.: "An efficient route to human bispecific IgG", NAT BIOTECHNOL, vol. 16, 1998, pages 677 - 681, XP002141015, DOI: doi:10.1038/nbt0798-677
ref_type: npl
severity: background
ref_id: - MORALES-KASTRESANA, A.; SANMAMED, M.F.; RODRIGUEZ, 1.; PALAZON, A.; MARTINEZ-FORERO, I.; LABIANO, S.; HERVAS-STUBBS, S.; SANGRO, B: "Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model", CLIN CANCER RES, vol. 19, 2013, pages 6151 - 6162, XP055176308, DOI: doi:10.1158/1078-0432.CCR-13-1189
ref_type: npl
severity: background
ref_id: - MUELLER, D.; FREY, K.; KONTERMANN, R.E.: "A novel antibody-4-1BB1 fusion protein for targeted costimulation in cancer immunotherapy", J. IMMUNOTHER, vol. 31, 2008, pages 714 - 722, XP009183889
ref_type: npl
severity: background
ref_id: - MURILLO, 0.; DUBROT, J.; PALAZON, A.; ARINA, A.; AZPILIKUETA, A.; ALFARO, C.; SOLANO, S.; OCHOA, M.C.; BERASAIN, C.; GABARI, I. ET: "In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb", EUR J IMMUNOL, vol. 39, 2009, pages 2424 - 2436
ref_type: npl
severity: background
ref_id: - NARAZAKI, H.; ZHU, Y.; LUO, L.; ZHU, G.; CHEN, L.: "CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells", BLOOD, vol. 115, 2010, pages 1941 - 1948, XP055034669, DOI: doi:10.1182/blood-2008-12-192591
ref_type: npl
severity: background
ref_id: - NISHIMOTO, H.; LEE, S.W.; HONG, H.; POTTER, K.G.; MAEDA-YAMAMOTO, M.; KINOSHITA, T.; KAWAKAMI, Y.; MITTLER, R.S.; KWON, B.S.; WARE: "Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor", BLOOD, vol. 106, 2005, pages 4241 - 4248
ref_type: npl
severity: background
ref_id: - OLOFSSON, P.S.; SODERSTROM, L.A.; WAGSATER, D.; SHEIKINE, Y.; OCAYA, P.; LANG, P.; RABU, C.; CHEN, L.; RUDLING, M.; AUKRUST, P. ET: "CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice.", CIRCULATION, vol. 117, 2008, pages 1292 - 1301, XP055052079, DOI: doi:10.1161/CIRCULATIONAHA.107.699173
ref_type: npl
severity: background
ref_id: - PALAZON, A.; TEIJEIRA, A.; MARTINEZ-FORERO, I.; HERVAS-STUBBS, S.; RONCAL, C.; PENUELAS, I.; DUBROT, J.; MORALES-KASTRESANA, A.; P: "Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes", CANCER RES, vol. 71, 2011, pages 801 - 811
ref_type: npl
severity: background
ref_id: - SCHWARZ, H.; VALBRACHT, J.; TUCKWELL, J.; VON KEMPIS, J.; LOTZ, M.: "ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages", BLOOD, vol. 85, 1995, pages 1043 - 1052
ref_type: npl
severity: background
ref_id: - SHAO, Z.; SCHWARZ, H.: "CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction", J LEUKOC BIOL, vol. 89, 2011, pages 21 - 29
ref_type: npl
severity: background
ref_id: - SHI, W.; SIEMANN, D.W.: "Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment", ANTICANCER RES, vol. 26, 2006, pages 3445 - 3453
ref_type: npl
severity: background
ref_id: - SIMEONE, E.; ASCIERTO, P.A.: "Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1", J IMMUNOTOXICOL, vol. 9, 2012, pages 241 - 247, XP009181173, DOI: doi:10.3109/1547691X.2012.678021
ref_type: npl
severity: background
ref_id: - SNELL, L.M.; LIN, G.H.; MCPHERSON, A.J.; MORAES, T.J.; WATTS, T.H.: "T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy", IMMUNOL REV, vol. 244, 2011, pages 197 - 217
ref_type: npl
severity: background
ref_id: - STAGG, J.; LOI, S.; DIVISEKERA, U.; NGIOW, S.F.; DURET, H.; YAGITA, H.; TENG, M.W.; SMYTH, M.J.: "Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD- or anti-CD137 mAb therapy.", PROC NATL ACAD SCI U S A, vol. 108, 2011, pages 7142 - 7147, XP055079201, DOI: doi:10.1073/pnas.1016569108
ref_type: npl
severity: background
ref_id: - TENG, M.W.; SHARKEY, J.; MCLAUGHLIN, N.M.; EXLEY, M.A.; SMYTH, M.J.: "CDld-based combination therapy eradicates established tumors in mice", J IMMUNOL, vol. 183, 2009, pages 1911 - 1920
ref_type: npl
severity: background
ref_id: - VON KEMPIS, J.; SCHWARZ, H.; LOTZ, M.: "Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin", OSTEOARTHRITIS CARTILAGE, vol. 5, 1997, pages 394 - 406, XP009005285, DOI: doi:10.1016/S1063-4584(97)80044-1
ref_type: npl
severity: background
ref_id: - WEI, H.; ZHAO, L.; LI, W.; FAN, K.; QIAN, W.; HOU, S.; WANG, H.; DAI, M.; HELLSTROM, I.; HELLSTROM, K.E.: "Combinatorial PD-1 blockade and CD 137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.", PLOS ONE, vol. 8, 2013, pages E84927
ref_type: npl
severity: background
ref_id: - WEI H.; ZHAO L.; HELLSTROM 1.; HELLSTROM K.E.; GUO Y.: "Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy", ONCOLMMUNOLOGY, vol. 3, no. 4, 2014, pages E28248
ref_type: npl
severity: background
ref_id: - WILCOX, R.A.; CHAPOVAL, A.I.; GORSKI, KS.; OTSUJI, M.; SHIN, T.; FLIES, D.B.; TAMADA, K.; MITTLER, R.S.; TSUCHIYA, H.; PARDOLL, D.: "Cutting edge: Expression of functional CD137 receptor by dendritic cells", J IMMUNOL, vol. 168, 2002, pages 4262 - 4267
ref_type: npl
severity: background
ref_id: - WILCOX, R.A.; TAMADA, K.; FLIES, D.B.; ZHU, G.; CHAPOVAL, A.I.; BLAZAR, B.R.; KAST, W.M.; CHEN, L.: "Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo", BLOOD, vol. 103, 2004, pages 177 - 184
ref_type: npl
severity: background
ref_id: - ZHANG, N.; SADUN, R.E.; ARIAS, R.S.; FLANAGAN, M.L.; SACHSMAN, S.M.; NIEN, Y; KHAWLI, L.A.; HU, P.; EPSTEIN, A.L.: "Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors", CLIN. CANCER RES., vol. 13, 2007, pages 2758 - 2767, XP055186494, DOI: doi:10.1158/1078-0432.CCR-06-2343
ref_type: npl
severity: background
ref_id: - ZHANG, X.; VOSKENS, C.J.; SALLIN, M.; MANIAR, A.; MONTES, C.L.; ZHANG, Y.; LIN, W.; LI, G.; BURCH, E.; TAN, M. ET AL.: "CD137 promotes proliferation and survival of human B cells", J IMMUNOL, vol. 184, 2010, pages 787 - 795
ref_type: npl
severity: background
ref_id: - EDWIN BREMER: "Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy", ISRN ONCOLOGY, vol. 176, no. 2, 1 January 2013 (2013-01-01), pages 974 - 25, XP055184622, ISSN: 2090-5661, DOI: 10.1186/1479-5876-9-204
ref_type: npl
severity: background
ref_id: - N. ZHANG ET AL: "Targeted and Untargeted CD137L Fusion Proteins for the Immunotherapy of Experimental Solid Tumors", CLINICAL CANCER RESEARCH, vol. 13, no. 9, 1 May 2007 (2007-05-01), pages 2758 - 2767, XP055186494, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-2343
ref_type: npl
severity: background
ref_id: - A. WYZGOL ET AL: "Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 3, 1 August 2009 (2009-08-01), pages 1851 - 1861, XP055015511, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0802597
ref_type: npl
severity: background
ref_id: WO2013164694A1
ref_type: patent
severity: background
ref_id: WO2016075278A1
ref_type: patent
severity: background
ref_id: WO2010010051A1
ref_type: patent
severity: background
ref_id: WO2015095423A2
ref_type: patent
severity: background
ref_id: - S. CHEN ET AL: "Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 2, 11 November 2014 (2014-11-11), US, pages 149 - 160, XP055293412, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0118
ref_type: npl
severity: background
ref_id: - SHINDO Y ET AL: "Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 35, no. 1, 1 January 2015 (2015-01-01), pages 129 - 136, XP002746546, ISSN: 0250-7005
ref_type: npl
severity: background
ref_id: - HORNIG NORA ET AL: "Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINGS INC, US, vol. 35, no. 5, 1 June 2012 (2012-06-01), pages 418 - 429, XP009163394, ISSN: 1524-9557, DOI: 10.1097/CJI.0B013E3182594387
ref_type: npl
severity: background
ref_id: - NORA HORNIG ET AL: "Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 62, no. 8, 1 August 2013 (2013-08-01), pages 1369 - 1380, XP055184710, ISSN: 0340-7004, DOI: 10.1007/s00262-013-1441-7
ref_type: npl
severity: background
ref_id: WO2010010051
ref_type: patent
severity: background
ref_id: WO2013164694
ref_type: patent
severity: background
ref_id: WO2015095423
ref_type: patent
severity: background
ref_id: WO2016075278
ref_type: patent
severity: novelty_destroying
ref_id: - S. CHEN ET AL, "Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model", CANCER IMMUNOLOGY RESEARCH, US, (20141111), vol. 3, no. 2, doi:10.1158/2326-6066.CIR-14-0118, ISSN 2326-6066, pages 149 - 160, XP055293412 [YD] 1-15 * abstract *
ref_type: npl
severity: obviousness
ref_id: - SHINDO Y ET AL, "Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20150101), vol. 35, no. 1, ISSN 0250-7005, pages 129 - 136, XP002746546 [Y] 1-15 * abstract *
ref_type: npl
severity: obviousness
ref_id: - HORNIG NORA ET AL, "Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINGS INC, US, (20120601), vol. 35, no. 5, doi:10.1097/CJI.0B013E3182594387, ISSN 1524-9557, pages 418 - 429, XP009163394 [YD] 1-15 * abstract *
ref_type: npl
severity: obviousness
ref_id: - NORA HORNIG ET AL, "Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, (20130801), vol. 62, no. 8, doi:10.1007/s00262-013-1441-7, ISSN 0340-7004, pages 1369 - 1380, XP055184710 [Y] 1-15 * abstract *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-11-15)